Corporate Snapshot – Edap Tms (FOCL)
Edap Tms (FOCL) has slipped ‑5.03 % over the 24‑hour window concluding at 03:13 PM Central Europe on Friday, 23 April 2026. The single share, now priced at USD 4.15, sits well below its 200‑day simple moving average of USD 4.40, signalling a prolonged bearish trend.
Market Fundamentals
| Metric | Value |
|---|---|
| Current Market Cap | USD 200.8 million |
| Shares Outstanding | 46 million |
| Volume (last 24 h) | USD 127.4 k |
| 52‑Week High | USD 6.40 (08/04/2026) |
| 52‑Week Low | USD 1.75 (10/28/2025) |
The drop of ‑12.45 % since the end of March underscores the company’s struggle to sustain momentum in a crowded therapeutic‑ultrasound niche. With a current valuation far below its 52‑week peak, investors are left to question whether the firm can capitalize on its technology without a decisive strategic pivot.
Comparative Peer Performance
| Stock | Recent Move | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Akwel (AKW.PA) | +0.97 % | EUR 6.38 | EUR 180 m | 12.49 |
| Lanson‑bcc (ALLAN.PA) | 0 % | EUR 25.8 | EUR 189.3 m | 11.82 |
| Les Hotels Baverez (ALLHB.PA) | +2.13 % | EUR 72 | EUR 185.6 m | 86.99 |
| Tge Value Creative Solu (BEBE) | 0 % | USD 10.1 | USD 202 m | – |
| Transgene (TNG.PA) | –0.59 % | EUR 0.68 | EUR 205.2 m | – |
Compared with its peers, Edap Tms’ decline is stark. While Akwel and Lanson‑bcc hold modest gains, and TGE Value Creative Solu remains flat, Edap’s fall is a clear warning sign. Even the beleaguered Transgene, trading near its own 52‑week low, is only marginally down, illustrating the relative severity of Edap’s slide.
Strategic Context
EDAP TMS SA, headquartered in Vaulx‑en‑Velin, France, specializes in minimally invasive therapeutic ultrasound for urology, tumor removal, prostate cancer, and infectious diseases. Since its 1997 Nasdaq debut, the company has been positioned at the intersection of medical innovation and market volatility. The current price trajectory suggests that market participants are questioning whether the company’s technology can generate sufficient revenue streams or whether it is simply lagging behind competitors who are capitalizing on the expanding therapeutic ultrasound market.
Bottom Line
Edap Tms’ ‑5.03 % day‑to‑day decline, coupled with a sustained slide of ‑12.45 % since the previous month, reflects a critical juncture for the firm. With a market cap of USD 200.8 million and a share price well below its 200‑day average, investors face a stark choice: bet on a turnaround or exit before the company’s valuation erodes further. The comparative performance of peer stocks, many of which are flat or modestly gaining, underscores that Edap’s momentum is not merely a temporary wobble but a potentially systemic issue that demands urgent strategic intervention.
